Teijin Pharma and Novartis have signed an exclusive global licence agreement for an investigational preclinical small molecule candidate for proteinuric kidney diseases.

Under the licence deal, Novartis will gain exclusive global rights for the research, development, manufacturing, and commercialisation of the candidate for all potential indications.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the agreements, Novartis will make $30m in an upfront cash payment to Teijin Pharma.

Teijin Pharma is also eligible for up to $200m in potential development and commercial milestone payments along with further additional sales milestones as well as tiered annual net sales royalties.

The company discovered the new investigational small molecule candidate at a drug development base in Tokyo, the Teijin Institute for Biomedical Research.

It stated that the candidate is believed to impact the pathogenesis of several kidney diseases and works in a genetically validated pathway.

Teijin Pharma is laying the foundation for quickly delivering a new therapy for patients globally by licensing the investigational compound to Novartis.

It is committed to developing new therapies for diseases that do not have effective treatment.

The company plans to continue to pursue collaboration to increase the value of the pharmaceutical it researches and develops in-house.

Last month, Teijin and Axcelead announced a basic agreement on a capital and business alliance for establishing a drug discovery research joint venture (JV) company.

The new JV will primarily utilise Teijin Pharma’s drug discovery research capabilities, facilities, personnel, technologies, and equipment.

It is anticipated to increase drug discovery support services globally using Teijin and Axcelead’s combined strengths in drug-discovery knowledge, technology, and assets.

Early R&D projects coverage on Pharmaceutical Technology is supported by Mimotopes.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.